Peptic ulcer in rheumatoid arthritis

D Farah, R D Sturrock, and R I Russell

From the Department of Gastroenterology and the Centre for Rheumatic Diseases, Royal Infirmary, Glasgow

Summary In a study of patients attending a rheumatology clinic 230 unselected patients, 185 with rheumatoid arthritis (RA) and 45 with other rheumatic disorders (non-RA), were examined by endoscopy and a detailed history of symptoms referable to the gastrointestinal tract was taken. A peptic ulcer was found in 67 (36%) of the patients and in 13 (29%) of the non-RA group. Gastric ulceration was more common in the group with RA (32 patients (17%) compared with three patients (7%) in the non-RA group); 17/32 (53%) patients with RA and gastric ulcer were asymptomatic. In the group with RA, of those with gastric ulcer 20/32 (63%) were smokers compared with only 40/118 (34%) of the non-ulcer group. There was no difference in the duration of rheumatic disease or non-steroidal anti-inflammatory drug (NSAID) treatment between the ulcer and non-ulcer groups. Treatment with H2 receptor antagonist and maintenance of NSAID treatment resulted in healing in 26 out of 29 (90%) patients with gastric ulcer and 23 out of 27 (85%) patients with duodenal ulcer.

Key words: non-steroidal anti-inflammatory drugs, H2 antagonists, arthritis.

There has been much recent interest in the association between peptic ulceration, non-steroidal anti-inflammatory drugs (NSAIDs), and rheumatoid arthritis (RA). The Committee on Safety of Medicines has drawn attention to the risks of gastrointestinal haemorrhage in elderly patients receiving NSAIDs, and several reports have confirmed this association. Iron deficiency anaemia is a common feature of RA and is often caused by an asymptomatic peptic ulcer. The aetiology of peptic ulceration in RA is controversial, and it is not clear whether the apparent increase in peptic ulceration in this condition is due to the disease itself or to the drugs commonly used in treatment. We have, therefore, studied the prevalence of peptic ulceration in our patients with RA attending a rheumatology clinic, and compared them with subjects with other rheumatic diseases.

Patients and methods

A series of consecutive patients with RA attending a rheumatology outpatient clinic were asked if they would agree to fibre optic endoscopy and were then enrolled in the study after informed consent had been given. All were receiving regular NSAID treatment. A detailed history of gastrointestinal symptoms was taken, recording the presence of nausea, vomiting, epigastric pain, heartburn, flatulence, and acid eructation, together with a record of smoking habits and details of steroid and NSAID treatment. Patients studied did not have anorexia or weight loss and had never had haematemesis or melaena. A family history of peptic ulcer was sought in each case. Fifty-six individuals who had endoscopic evidence of a peptic ulcer were treated with ranitidine 150 mg twice a day and their NSAID was continued. Repeat endoscopy was performed at monthly intervals until the ulcer healed. A group of 45 patients who were receiving regular NSAID treatment and had a variety of chronic rheumatic diseases, including ankylosing spondylitis, osteoarthritis, gout, and systemic lupus erythematosus, were also included in the study.

Statistical analysis

Differences in proportions were calculated by analysis with a continuity correction (Yates's correction) for small numbers. Confidence intervals are quoted for the differences observed.
Results

One hundred and eighty five patients with RA and 45 non-RA patients were studied. The two groups were matched for age by decades—mean age of patients with RA 55 years (range 19-82), non-RA patients 47-5 years (range 30-72). Table 1 shows the prevalence and site of peptic ulceration in the two groups. It can be seen that there was an increased prevalence in the RA group with a large increase in gastric ulceration which was not significant at the 5% level owing to the wide confidence intervals observed—a problem arising from the relatively small sample size.

A surprising finding was the low prevalence of gastrointestinal symptoms in the RA group with a gastric ulcer, 14/32 (44%), when compared with the non-ulcer group, 81/118 (69%). In both the RA and non-RA groups the mean age of patients with gastric ulcer was higher than that of patients with a duodenal ulcer (DU) and non-ulcer patients, and smoking was a major factor in predisposing to peptic ulceration in all patients (Table 2), with a suggestion that there were more smokers in the RA group as a whole. There was no correlation between peptic ulceration, disease duration, or NSAID dosage in the RA group. Steroids were taken by only four patients with RA, of whom two had an ulcer, with one non-RA patient taking regular steroids.

Table 1  Occurrence and site of peptic ulcer

<table>
<thead>
<tr>
<th>RA (n=185)</th>
<th>Non-RA (n=45)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
</tr>
<tr>
<td>Gastric ulcer</td>
<td>32</td>
</tr>
<tr>
<td>Duodenal ulcer</td>
<td>29</td>
</tr>
<tr>
<td>Combined</td>
<td>6</td>
</tr>
<tr>
<td>Total</td>
<td>67</td>
</tr>
</tbody>
</table>

*χ²=2.40 (two tailed), p=0.117. 95% confidence interval=0.008 to 0.19.

Discussion

This survey has demonstrated a high prevalence of peptic ulceration in patients with RA who are taking NSAIDs on a regular basis. The patient group used for comparison were also receiving NSAID treatment and yet there was a greater prevalence of gastric ulceration in the RA group which could not be accounted for by factors such as age or quantity and number of NSAIDs consumed. Smoking was certainly a factor associated with peptic ulceration in RA, and this confirms the findings of a similar, albeit retrospective, survey of a rheumatology clinic. Gastroenterologists and rheumatologists have had the strong clinical impression that NSAID treatment, and in particular indomethacin, can cause prepyloric ulceration in RA. In this study prepyloric ulceration was observed more commonly in the patients with RA but was not associated with any particular NSAID. One of the difficulties in a study such as this is the possibility of selection bias confounding the results, but every effort was made to ensure that the patients enrolled in the study were representative of those routinely monitored in the rheumatology clinic.

The treatment of peptic ulceration in patients with RA is difficult as most require continuation of their NSAID to control the distressing symptoms of their arthritis, and yet the antirheumatic drug may be the cause of their ulcer. Several studies have explored the effect of an H₂ antagonist on ulcer healing with continuation of NSAID treatment. Most studies have been uncontrolled and have shown that ulcers do heal at a rate similar to that observed in non-RA
patients. One report, however, demonstrated a high ulcer healing rate on placebo, and another emphasised that H2 antagonists may relieve ulcer symptoms without healing and result in the risk of a silent perforation. Our own uncontrolled study has shown a slightly reduced ulcer healing rate in the RA group maintained on NSAIDs and treated with ranitidine, when compared with the healing rates reported for non-NSAID associated peptic ulceration.

Peptic ulceration in RA is often asymptomatic and this may be partly owing to the analgesic effect of the NSAIDs taken by these patients. Endoscopy is the only sure way to establish the presence of ulceration and to monitor the response to treatment. Our own study suggests that other factors may be contributing to the high prevalence of peptic ulceration in RA, as well as NSAIDs. Smoking is important but a mucosal defect may also be contributory as atrophic gastritis is a well recognised feature of RA. The natural history of peptic ulceration is unknown and hence treatment remains empirical. Long term controlled studies of the effects of H2 blockers, and also of agents which enhance the integrity of the gastric mucosa, are required to determine the optimum therapeutic approach to the patient with RA and a peptic ulcer.

References